Incyte scraps planned Phase 3 ovarian cancer study
Incyte will not proceed with the planned Phase 3 MAESTRA-3 trial of selective CDK2 inhibitor INCB123.
Related stories
FAA Grounds Flights, Airline Shares Decline Late in Session
The FAA halted flights, citing “extraordinary circumstances and for reasons of safety.” American Airlines closed down 1% at $13.17 and was recently trading at $12.94 after hours.
M impact | EQUITY | Nov 13, 2026, 10:22 PM UTC
US Airlines Fall in Extended Trading Amid Nationwide Ground Stop
American Airlines, Delta and United fell more than 1%; JetBlue fell 3%.
M impact | EQUITY | Nov 13, 2026, 10:22 PM UTC
Douglas Elliman Names Heather Capriola CFO; James Kirkland Retires
Douglas Elliman appointed Heather Capriola CFO as James Kirkland retires.
L impact | EQUITY | Nov 13, 2026, 10:18 PM UTC
AiRWA Agrees to Sell 1,800,000 Shares in $1.5 Million Private Placement
AiRWA agreed to sell 1,800,000 shares in a $1.5 million private placement.
L impact | EQUITY | Nov 13, 2026, 10:16 PM UTC
Booking Holdings Raises €3.55 Billion in Senior Note Offerings
Booking Holdings issued €3.55 billion of senior unsecured notes across four maturities from 2029 to 2038. The tranches carry annual interest rates of 3.950% to 5.000%, with interes
M impact | EQUITY | Nov 13, 2026, 10:13 PM UTC
Booking Holdings Issues €3.55 Billion in Senior Unsecured Notes
M impact | EQUITY | Nov 13, 2026, 10:13 PM UTC